Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Review Article

Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques

Author(s): Fatemeh Tavakoli, Sara Sadat Khatami, Fatemeh Momeni, Javid Azadbakht* and Faezeh Ghasemi*

Volume 24, Issue 5, 2021

Published on: 01 September, 2020

Page: [605 - 623] Pages: 19

DOI: 10.2174/1386207323666200901101955

Price: $65

Abstract

Cervical malignancy is known as one of the important cancers which is originated from cervix. This malignancy has been observed in women infected with papillomavirus who had regular oral contraceptives, multiple pregnancies, and sexual relations. Early and fast cervical cancer diagnosis is known as two important aspects of cervical cancer therapy. Several investigations indicated that early and fast detection of cervical cancer could be associated with better treatment process and increasing survival rate of patients with this malignancy. Imaging techniques are very important diagnosis tools that could be employed for diagnosis and following responses to therapy in various cervical cancer stages. Multiple lines of evidence indicated that utilization of imaging techniques is related to some limitations (i.e. high cost, and invasive effects). Hence, it seems that along with using imaging techniques, finding and developing new biomarkers could be useful in the diagnosis and treatment of subjects with cervical cancer. Taken together, many studies showed that a variety of biomarkers including, several proteins, mRNAs, microRNAs, exosomes and polymorphisms might be introduced as prognostic, diagnostic and therapeutic biomarkers in cervical cancer therapy. In this review article, we highlighted imaging techniques as well as novel biomarkers for the diagnosis of cervical cancer.

Keywords: Cervical cancer, imaging techniques, diagnostic biomarkers, prognostic biomarkers, therapeutic biomarkers, risk factors.

Next »
[1]
Gupta, P.; Sharma, U.; Gupta, P.; Siripurapu, K.B.; Maurya, R. Evolvosides C–E, flavonol-4′-O-triglycosides from evolvulus alsinoides and their anti-stress activity [corrected Bioorg. Med. Chem., 2013, 21(5), 1116-1122.
[http://dx.doi.org/10.1016/j.bmc.2012.12.040] [PMID: 23357036]
[2]
Ali, I.; Wani, W.A.; Saleem, K.; Hseih, M-F. Design and synthesis of thalidomide based dithiocarbamate Cu (II), Ni (II) and Ru (III) complexes as anticancer agents. Polyhedron, 2013, 56, 134-143.
[http://dx.doi.org/10.1016/j.poly.2013.03.056]
[3]
Ali, I.; Lone, M.N.; Al-Othman, Z.A.; Al-Warthan, A.; Sanagi, M.M. Heterocyclic Scaffolds: Centrality in Anticancer Drug Development. Curr. Drug Targets, 2015, 16(7), 711-734.
[http://dx.doi.org/10.2174/1389450116666150309115922] [PMID: 25751009]
[4]
Ali, I. Nano anti-cancer drugs: pros and cons and future perspectives. Curr. Cancer Drug Targets, 2011, 11(2), 131-134.
[http://dx.doi.org/10.2174/156800911794328457] [PMID: 21062238]
[5]
Ali, I.; Aboul-Enein, H.Y.; Ghanem, A. Enantioselective toxicity and carcinogenesis. Curr. Pharm. Anal., 2005, 1(1), 109-125.
[http://dx.doi.org/10.2174/1573412052953328]
[6]
Ali, I.; Saleem, K.; Wesselinova, D.; Haque, A. Synthesis, DNA binding, hemolytic, and anti-cancer assays of curcumin I-based ligands and their ruthenium (III) complexes. Med. Chem. Res., 2013, 22(3), 1386-1398.
[http://dx.doi.org/10.1007/s00044-012-0133-8]
[7]
Ali, I.; Saleem, K.; Aboul-Enein, H.Y.; Rather, A. Social Aspects of Cancer Genesis. Cancer Ther., 2011, 8.
[8]
Kishwar, S.; Waseem, L.M. H. Ming, J. Mohamad, Imran, A. Future Med. Chem., 2013, 5(2), 135-146.
[PMID: 23360139]
[9]
Ali, I.; Wani, W.A.; Saleem, K.; Wesselinova, D. Syntheses, DNA binding and anticancer profiles of L-glutamic acid ligand and its copper(II) and ruthenium(III) complexes. Med. Chem., 2013, 9(1), 11-21.
[http://dx.doi.org/10.2174/157340613804488297] [PMID: 22741786]
[10]
Ali, I.; Saleem, K.; Uddin, R.; Haque, A.; El-Azzouny, A. Natural products: human friendly anti-cancer medications. Egypt Pharm J, 2010, 9(2), 133-179.
[11]
Ali, I.; Wani, W.A.; Haque, A.; Saleem, K. Glutamic acid and its derivatives: candidates for rational design of anticancer drugs. Future Med. Chem., 2013, 5(8), 961-978.
[http://dx.doi.org/10.4155/fmc.13.62] [PMID: 23682571]
[12]
Ali, I.; Wani, W.A.; Saleem, K.; Hsieh, M-F. Anticancer metallodrugs of glutamic acid sulphonamides: in silico, DNA binding, hemolysis and anticancer studies. RSC Advances, 2014, 4(56), 29629-29641.
[http://dx.doi.org/10.1039/C4RA02570A]
[13]
Ali, I.; Haque, A.; Wani, W.A.; Saleem, K.; Al Za’abi, M. Analyses of anticancer drugs by capillary electrophoresis: a review. Biomed. Chromatogr., 2013, 27(10), 1296-1311.
[http://dx.doi.org/10.1002/bmc.2953] [PMID: 23843248]
[14]
Ali, I.; Lone, M.N.; Suhail, M.; Mukhtar, S.D.; Asnin, L. Danish Mukhtar S, Asnin L: Advances in nanocarriers for anticancer drugs delivery. Curr. Med. Chem., 2016, 23(20), 2159-2187.
[http://dx.doi.org/10.2174/0929867323666160405111152] [PMID: 27048343]
[15]
Ali, I. Nano drugs: novel agents for cancer chemo-therapy. Curr. Cancer Drug Targets, 2011, 11(2), 130-130.
[http://dx.doi.org/10.2174/156800911794328466] [PMID: 21247391]
[16]
Ali, I.; Rahis-Uddin, ; Salim, K.; Rather, M.A.; Wani, W.A.; Haque, A. Advances in nano drugs for cancer chemotherapy. Curr. Cancer Drug Targets, 2011, 11(2), 135-146.
[http://dx.doi.org/10.2174/156800911794328493] [PMID: 21158724]
[17]
GBD 2017 Colorectal Cancer Collaborators. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol., 2019, 4(12), 913-933.
[http://dx.doi.org/10.1016/S2468-1253(19)30345-0] [PMID: 31648977]
[18]
Fitzmaurice, C.; Abate, D.; Abbasi, N.; Abbastabar, H.; Abd-Allah, F.; Abdel-Rahman, O.; Abdelalim, A.; Abdoli, A.; Abdollahpour, I.; Abdulle, A.S.M.; Abebe, N.D.; Abraha, H.N.; Abu-Raddad, L.J.; Abualhasan, A.; Adedeji, I.A.; Advani, S.M.; Afarideh, M.; Afshari, M.; Aghaali, M.; Agius, D.; Agrawal, S.; Ahmadi, A.; Ahmadian, E.; Ahmadpour, E.; Ahmed, M.B.; Akbari, M.E.; Akinyemiju, T.; Al-Aly, Z.; AlAbdulKader, A.M.; Alahdab, F.; Alam, T.; Alamene, G.M.; Alemnew, B.T.T.; Alene, K.A.; Alinia, C.; Alipour, V.; Aljunid, S.M.; Bakeshei, F.A.; Almadi, M.A.H.; Almasi-Hashiani, A.; Alsharif, U.; Alsowaidi, S.; Alvis-Guzman, N.; Amini, E.; Amini, S.; Amoako, Y.A.; Anbari, Z.; Anber, N.H.; Andrei, C.L.; Anjomshoa, M.; Ansari, F.; Ansariadi, A.; Appiah, S.C.Y.; Arab-Zozani, M.; Arabloo, J.; Arefi, Z.; Aremu, O.; Areri, H.A.; Artaman, A.; Asayesh, H.; Asfaw, E.T.; Ashagre, A.F.; Assadi, R.; Ataeinia, B.; Atalay, H.T.; Ataro, Z.; Atique, S.; Ausloos, M.; Avila-Burgos, L.; Avokpaho, E.F.G.A.; Awasthi, A.; Awoke, N.; Ayala Quintanilla, B.P.; Ayanore, M.A.; Ayele, H.T.; Babaee, E.; Bacha, U.; Badawi, A.; Bagherzadeh, M.; Bagli, E.; Balakrishnan, S.; Balouchi, A.; Bärnighausen, T.W.; Battista, R.J.; Behzadifar, M.; Behzadifar, M.; Bekele, B.B.; Belay, Y.B.; Belayneh, Y.M.; Berfield, K.K.S.; Berhane, A.; Bernabe, E.; Beuran, M.; Bhakta, N.; Bhattacharyya, K.; Biadgo, B.; Bijani, A.; Bin Sayeed, M.S.; Birungi, C.; Bisignano, C.; Bitew, H.; Bjørge, T.; Bleyer, A.; Bogale, K.A.; Bojia, H.A.; Borzì, A.M.; Bosetti, C.; Bou-Orm, I.R.; Brenner, H.; Brewer, J.D.; Briko, A.N.; Briko, N.I.; Bustamante-Teixeira, M.T.; Butt, Z.A.; Carreras, G.; Carrero, J.J.; Carvalho, F.; Castro, C.; Castro, F.; Catalá-López, F.; Cerin, E.; Chaiah, Y.; Chanie, W.F.; Chattu, V.K.; Chaturvedi, P.; Chauhan, N.S.; Chehrazi, M.; Chiang, P.P.; Chichiabellu, T.Y.; Chido-Amajuoyi, O.G.; Chimed-Ochir, O.; Choi, J.J.; Christopher, D.J.; Chu, D.T.; Constantin, M.M.; Costa, V.M.; Crocetti, E.; Crowe, C.S.; Curado, M.P.; Dahlawi, S.M.A.; Damiani, G.; Darwish, A.H.; Daryani, A.; das Neves, J.; Demeke, F.M.; Demis, A.B.; Demissie, B.W.; Demoz, G.T.; Denova-Gutiérrez, E.; Derakhshani, A.; Deribe, K.S.; Desai, R.; Desalegn, B.B.; Desta, M.; Dey, S.; Dharmaratne, S.D.; Dhimal, M.; Diaz, D.; Dinberu, M.T.T.; Djalalinia, S.; Doku, D.T.; Drake, T.M.; Dubey, M.; Dubljanin, E.; Duken, E.E.; Ebrahimi, H.; Effiong, A.; Eftekhari, A.; El Sayed, I.; Zaki, M.E.S.; El-Jaafary, S.I.; El-Khatib, Z.; Elemineh, D.A.; Elkout, H.; Ellenbogen, R.G.; Elsharkawy, A.; Emamian, M.H.; Endalew, D.A.; Endries, A.Y.; Eshrati, B.; Fadhil, I.; Fallah, V.; Faramarzi, M.; Farhangi, M.A.; Farioli, A.; Farzadfar, F.; Fentahun, N.; Fernandes, E.; Feyissa, G.T.; Filip, I.; Fischer, F.; Fisher, J.L.; Force, L.M.; Foroutan, M.; Freitas, M.; Fukumoto, T.; Futran, N.D.; Gallus, S.; Gankpe, F.G.; Gayesa, R.T.; Gebrehiwot, T.T.; Gebremeskel, G.G.; Gedefaw, G.A.; Gelaw, B.K.; Geta, B.; Getachew, S.; Gezae, K.E.; Ghafourifard, M.; Ghajar, A.; Ghashghaee, A.; Gholamian, A.; Gill, P.S.; Ginindza, T.T.G.; Girmay, A.; Gizaw, M.; Gomez, R.S.; Gopalani, S.V.; Gorini, G.; Goulart, B.N.G.; Grada, A.; Ribeiro Guerra, M.; Guimaraes, A.L.S.; Gupta, P.C.; Gupta, R.; Hadkhale, K.; Haj-Mirzaian, A.; Haj-Mirzaian, A.; Hamadeh, R.R.; Hamidi, S.; Hanfore, L.K.; Haro, J.M.; Hasankhani, M.; Hasanzadeh, A.; Hassen, H.Y.; Hay, R.J.; Hay, S.I.; Henok, A.; Henry, N.J.; Herteliu, C.; Hidru, H.D.; Hoang, C.L.; Hole, M.K.; Hoogar, P.; Horita, N.; Hosgood, H.D.; Hosseini, M.; Hosseinzadeh, M.; Hostiuc, M.; Hostiuc, S.; Househ, M.; Hussen, M.M.; Ileanu, B.; Ilic, M.D.; Innos, K.; Irvani, S.S.N.; Iseh, K.R.; Islam, S.M.S.; Islami, F.; Jafari Balalami, N.; Jafarinia, M.; Jahangiry, L.; Jahani, M.A.; Jahanmehr, N.; Jakovljevic, M.; James, S.L.; Javanbakht, M.; Jayaraman, S.; Jee, S.H.; Jenabi, E.; Jha, R.P.; Jonas, J.B.; Jonnagaddala, J.; Joo, T.; Jungari, S.B.; Jürisson, M.; Kabir, A.; Kamangar, F.; Karch, A.; Karimi, N.; Karimian, A.; Kasaeian, A.; Kasahun, G.G.; Kassa, B.; Kassa, T.D.; Kassaw, M.W.; Kaul, A.; Keiyoro, P.N.; Kelbore, A.G.; Kerbo, A.A.; Khader, Y.S.; Khalilarjmandi, M.; Khan, E.A.; Khan, G.; Khang, Y.H.; Khatab, K.; Khater, A.; Khayamzadeh, M.; Khazaee-Pool, M.; Khazaei, S.; Khoja, A.T.; Khosravi, M.H.; Khubchandani, J.; Kianipour, N.; Kim, D.; Kim, Y.J.; Kisa, A.; Kisa, S.; Kissimova-Skarbek, K.; Komaki, H.; Koyanagi, A.; Krohn, K.J.; Bicer, B.K.; Kugbey, N.; Kumar, V.; Kuupiel, D.; La Vecchia, C.; Lad, D.P.; Lake, E.A.; Lakew, A.M.; Lal, D.K.; Lami, F.H.; Lan, Q.; Lasrado, S.; Lauriola, P.; Lazarus, J.V.; Leigh, J.; Leshargie, C.T.; Liao, Y.; Limenih, M.A.; Listl, S.; Lopez, A.D.; Lopukhov, P.D.; Lunevicius, R.; Madadin, M.; Magdeldin, S.; El Razek, H.M.A.; Majeed, A.; Maleki, A.; Malekzadeh, R.; Manafi, A.; Manafi, N.; Manamo, W.A.; Mansourian, M.; Mansournia, M.A.; Mantovani, L.G.; Maroufizadeh, S.; Martini, S.M.S.; Mashamba-Thompson, T.P.; Massenburg, B.B.; Maswabi, M.T.; Mathur, M.R.; McAlinden, C.; McKee, M.; Meheretu, H.A.A.; Mehrotra, R.; Mehta, V.; Meier, T.; Melaku, Y.A.; Meles, G.G.; Meles, H.G.; Melese, A.; Melku, M.; Memiah, P.T.N.; Mendoza, W.; Menezes, R.G.; Merat, S.; Meretoja, T.J.; Mestrovic, T.; Miazgowski, B.; Miazgowski, T.; Mihretie, K.M.M.; Miller, T.R.; Mills, E.J.; Mir, S.M.; Mirzaei, H.; Mirzaei, H.R.; Mishra, R.; Moazen, B.; Mohammad, D.K.; Mohammad, K.A.; Mohammad, Y.; Darwesh, A.M.; Mohammadbeigi, A.; Mohammadi, H.; Mohammadi, M.; Mohammadian, M.; Mohammadian-Hafshejani, A.; Mohammadoo-Khorasani, M.; Mohammadpourhodki, R.; Mohammed, A.S.; Mohammed, J.A.; Mohammed, S.; Mohebi, F.; Mokdad, A.H.; Monasta, L.; Moodley, Y.; Moosazadeh, M.; Moossavi, M.; Moradi, G.; Moradi-Joo, M.; Moradi-Lakeh, M.; Moradpour, F.; Morawska, L.; Morgado-da-Costa, J.; Morisaki, N.; Morrison, S.D.; Mosapour, A.; Mousavi, S.M.; Muche, A.A.; Muhammed, O.S.S.; Musa, J.; Nabhan, A.R.; Naderi, M.; Nagarajan, A.J.; Nagel, G.; Nahvijou, A.; Naik, G.; Najafi, F.; Naldi, L.; Nam, H.S.; Nasiri, N.; Nazari, J.; Negoi, I.; Neupane, S.; Newcomb, P.A.; Nggada, H.A.; Ngunjiri, J.W.; Nguyen, C.T.; Nikniaz, L.; Ningrum, D.N.A.; Nirayo, Y.L.; Nixon, M.R.; Nnaji, C.A.; Nojomi, M.; Nosratnejad, S.; Shiadeh, M.N.; Obsa, M.S.; Ofori-Asenso, R.; Ogbo, F.A.; Oh, I.H.; Olagunju, A.T.; Olagunju, T.O.; Oluwasanu, M.M.; Omonisi, A.E.; Onwujekwe, O.E.; Oommen, A.M.; Oren, E.; Ortega-Altamirano, D.D.V.; Ota, E.; Otstavnov, S.S.; Owolabi, M.O.; P A, M.; Padubidri, J.R.; Pakhale, S.; Pakpour, A.H.; Pana, A.; Park, E.K.; Parsian, H.; Pashaei, T.; Patel, S.; Patil, S.T.; Pennini, A.; Pereira, D.M.; Piccinelli, C.; Pillay, J.D.; Pirestani, M.; Pishgar, F.; Postma, M.J.; Pourjafar, H.; Pourmalek, F.; Pourshams, A.; Prakash, S.; Prasad, N.; Qorbani, M.; Rabiee, M.; Rabiee, N.; Radfar, A.; Rafiei, A.; Rahim, F.; Rahimi, M.; Rahman, M.A.; Rajati, F.; Rana, S.M.; Raoofi, S.; Rath, G.K.; Rawaf, D.L.; Rawaf, S.; Reiner, R.C.; Renzaho, A.M.N.; Rezaei, N.; Rezapour, A.; Ribeiro, A.I.; Ribeiro, D.; Ronfani, L.; Roro, E.M.; Roshandel, G.; Rostami, A.; Saad, R.S.; Sabbagh, P.; Sabour, S.; Saddik, B.; Safiri, S.; Sahebkar, A.; Salahshoor, M.R.; Salehi, F.; Salem, H.; Salem, M.R.; Salimzadeh, H.; Salomon, J.A.; Samy, A.M.; Sanabria, J.; Santric Milicevic, M.M.; Sartorius, B.; Sarveazad, A.; Sathian, B.; Satpathy, M.; Savic, M.; Sawhney, M.; Sayyah, M.; Schneider, I.J.C.; Schöttker, B.; Sekerija, M.; Sepanlou, S.G.; Sepehrimanesh, M.; Seyedmousavi, S.; Shaahmadi, F.; Shabaninejad, H.; Shahbaz, M.; Shaikh, M.A.; Shamshirian, A.; Shamsizadeh, M.; Sharafi, H.; Sharafi, Z.; Sharif, M.; Sharifi, A.; Sharifi, H.; Sharma, R.; Sheikh, A.; Shirkoohi, R.; Shukla, S.R.; Si, S.; Siabani, S.; Silva, D.A.S.; Silveira, D.G.A.; Singh, A.; Singh, J.A.; Sisay, S.; Sitas, F.; Sobngwi, E.; Soofi, M.; Soriano, J.B.; Stathopoulou, V.; Sufiyan, M.B.; Tabarés-Seisdedos, R.; Tabuchi, T.; Takahashi, K.; Tamtaji, O.R.; Tarawneh, M.R.; Tassew, S.G.; Taymoori, P.; Tehrani-Banihashemi, A.; Temsah, M.H.; Temsah, O.; Tesfay, B.E.; Tesfay, F.H.; Teshale, M.Y.; Tessema, G.A.; Thapa, S.; Tlaye, K.G.; Topor-Madry, R.; Tovani-Palone, M.R.; Traini, E.; Tran, B.X.; Tran, K.B.; Tsadik, A.G.; Ullah, I.; Uthman, O.A.; Vacante, M.; Vaezi, M.; Varona Pérez, P.; Veisani, Y.; Vidale, S.; Violante, F.S.; Vlassov, V.; Vollset, S.E.; Vos, T.; Vosoughi, K.; Vu, G.T.; Vujcic, I.S.; Wabinga, H.; Wachamo, T.M.; Wagnew, F.S.; Waheed, Y.; Weldegebreal, F.; Weldesamuel, G.T.; Wijeratne, T.; Wondafrash, D.Z.; Wonde, T.E.; Wondmieneh, A.B.; Workie, H.M.; Yadav, R.; Yadegar, A.; Yadollahpour, A.; Yaseri, M.; Yazdi-Feyzabadi, V.; Yeshaneh, A.; Yimam, M.A.; Yimer, E.M.; Yisma, E.; Yonemoto, N.; Younis, M.Z.; Yousefi, B.; Yousefifard, M.; Yu, C.; Zabeh, E.; Zadnik, V.; Moghadam, T.Z.; Zaidi, Z.; Zamani, M.; Zandian, H.; Zangeneh, A.; Zaki, L.; Zendehdel, K.; Zenebe, Z.M.; Zewale, T.A.; Ziapour, A.; Zodpey, S.; Murray, C.J.L. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol., 2019, 5(12), 1749-1768.
[http://dx.doi.org/10.1001/jamaoncol.2019.2996] [PMID: 31560378]
[19]
Ghasemi, F.; Shafiee, M.; Banikazemi, Z.; Pourhanifeh, M.H.; Khanbabaei, H.; Shamshirian, A.; Amiri Moghadam, S.; ArefNezhad, R.; Sahebkar, A.; Avan, A.; Mirzaei, H. Curcumin inhibits NF-kB and Wnt/β-catenin pathways in cervical cancer cells. Pathol. Res. Pract., 2019, 215(10)152556
[http://dx.doi.org/10.1016/j.prp.2019.152556] [PMID: 31358480]
[20]
Nahand, J.S.; Taghizadeh-Boroujeni, S.; Karimzadeh, M.; Borran, S.; Pourhanifeh, M.H.; Moghoofei, M.; Bokharaei-Salim, F.; Karampoor, S.; Jafari, A.; Asemi, Z.; Tbibzadeh, A.; Namdar, A.; Mirzaei, H. microRNAs: New prognostic, diagnostic, and therapeutic biomarkers in cervical cancer. J. Cell. Physiol., 2019, 234(10), 17064-17099.
[http://dx.doi.org/10.1002/jcp.28457] [PMID: 30891784]
[21]
Shafabakhsh, R.; Reiter, R.J.; Mirzaei, H.; Teymoordash, S.N.; Asemi, Z. Melatonin: A new inhibitor agent for cervical cancer treatment. J. Cell. Physiol., 2019, 234(12), 21670-21682.
[http://dx.doi.org/10.1002/jcp.28865] [PMID: 31131897]
[22]
Shrestha, A.D.; Neupane, D.; Vedsted, P.; Kallestrup, P. Cervical Cancer Prevalence, Incidence and Mortality in Low and Middle Income Countries: A Systematic Review. Asian Pac. J. Cancer Prev., 2018, 19(2), 319-324.
[PMID: 29479954]
[23]
Rabelo-Santos, S.H.; Termini, L.; Boccardo, E.; Derchain, S.; Longatto-Filho, A.; Andreoli, M.A.; Costa, M.C.; Lima Nunes, R.A.; Lucci Ângelo-Andrade, L.A.; Villa, L.L.; Zeferino, L.C. Strong SOD2 expression and HPV-16/18 positivity are independent events in cervical cancer. Oncotarget, 2018, 9(31), 21630-21640.
[http://dx.doi.org/10.18632/oncotarget.24850] [PMID: 29774090]
[24]
Yost, S.; Hoekstra, A. Cervical cancer in women over 65: An analysis of screening. Gynecol. Oncol. Rep., 2018, 25, 48-51.
[http://dx.doi.org/10.1016/j.gore.2018.05.010] [PMID: 30023421]
[25]
Swanson, M.; Ibrahim, S.; Blat, C.; Oketch, S.; Olwanda, E.; Maloba, M.; Huchko, M.J. Evaluating a community-based cervical cancer screening strategy in Western Kenya: a descriptive study. BMC Womens Health, 2018, 18(1), 116.
[http://dx.doi.org/10.1186/s12905-018-0586-0] [PMID: 29970063]
[26]
Gupta, R.; Gupta, S.; Mehrotra, R.; Sodhani, P. Cervical Cancer Screening in Resource-Constrained Countries: Current Status and Future Directions. Asian Pac. J. Cancer Prev., 2017, 18(6), 1461-1467.
[PMID: 28669152]
[27]
Davoodvandi, A.; Sahebnasagh, R.; Mardanshah, O.; Asemi, Z.; Nejati, M.; Shahrzad, M.K.; Mirzaei, H.R.; Mirzaei, H. Medicinal Plants As Natural Polarizers of Macrophages: Phytochemicals and Pharmacological Effects. Curr. Pharm. Des., 2019, 25(30), 3225-3238.
[http://dx.doi.org/10.2174/1381612825666190829154934] [PMID: 31465276]
[28]
Faghihloo, E.; Araei, Y.; Mohammadi, M.; Mirzaei, H.; Mohammadi, H.R.; Mokhtari-Azad, T. The effect of oxamflatin on the E-cadherin expression in gastric cancer cell line. Cancer Gene Ther., 2016, 23(11), 396-399.
[http://dx.doi.org/10.1038/cgt.2016.52] [PMID: 27767089]
[29]
Hashemi Goradel, N.; Ghiyami-Hour, F.; Jahangiri, S.; Negahdari, B.; Sahebkar, A.; Masoudifar, A.; Mirzaei, H. Nanoparticles as new tools for inhibition of cancer angiogenesis. J. Cell. Physiol., 2018, 233(4), 2902-2910.
[http://dx.doi.org/10.1002/jcp.26029] [PMID: 28543172]
[30]
Hesari, A.; Azizian, M.; Sheikhi, A.; Nesaei, A.; Sanaei, S.; Mahinparvar, N.; Derakhshani, M.; Hedayt, P.; Ghasemi, F.; Mirzaei, H. Chemopreventive and therapeutic potential of curcumin in esophageal cancer: Current and future status. Int. J. Cancer, 2019, 144(6), 1215-1226.
[http://dx.doi.org/10.1002/ijc.31947] [PMID: 30362511]
[31]
Honari, M.; Shafabakhsh, R.; Reiter, R.J.; Mirzaei, H.; Asemi, Z. Resveratrol is a promising agent for colorectal cancer prevention and treatment: focus on molecular mechanisms. Cancer Cell Int., 2019, 19, 180.
[http://dx.doi.org/10.1186/s12935-019-0906-y] [PMID: 31341423]
[32]
Mashreghi, M.; Azarpara, H.; Bazaz, M.R.; Jafari, A.; Masoudifar, A.; Mirzaei, H.; Jaafari, M.R. Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. J. Cell. Physiol., 2018, 233(4), 2949-2965.
[http://dx.doi.org/10.1002/jcp.26049] [PMID: 28608549]
[33]
Mirzaei, H.; Khoi, M.J.; Azizi, M.; Goodarzi, M. Can curcumin and its analogs be a new treatment option in cancer therapy? Cancer Gene Ther., 2016, 23(11), 410.
[http://dx.doi.org/10.1038/cgt.2016.47] [PMID: 27853147]
[34]
Mirzaei, H.; Naseri, G.; Rezaee, R.; Mohammadi, M.; Banikazemi, Z.; Mirzaei, H.R.; Salehi, H.; Peyvandi, M.; Pawelek, J.M.; Sahebkar, A. Curcumin: A new candidate for melanoma therapy? Int. J. Cancer, 2016, 139(8), 1683-1695.
[http://dx.doi.org/10.1002/ijc.30224] [PMID: 27280688]
[35]
Mirzaei, H.; Sahebkar, A.; Avan, A.; Jaafari, M.R.; Salehi, R.; Salehi, H.; Baharvand, H.; Rezaei, A.; Hadjati, J.; Pawelek, J.M.; Mirzaei, H.R. Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents. Curr. Med. Chem., 2016, 23(5), 455-463.
[http://dx.doi.org/10.2174/0929867323666151217122033] [PMID: 26674785]
[36]
Mirzaei, H.; Sahebkar, A.; Jaafari, M.R.; Hadjati, J.; Javanmard, S.H.; Mirzaei, H.R.; Salehi, R. PiggyBac as a novel vector in cancer gene therapy: current perspective. Cancer Gene Ther., 2016, 23(2-3), 45-47.
[http://dx.doi.org/10.1038/cgt.2015.68] [PMID: 26742580]
[37]
Mirzaei, H.; Sahebkar, A.; Sichani, L.S.; Moridikia, A.; Nazari, S.; Sadri Nahand, J.; Salehi, H.; Stenvang, J.; Masoudifar, A.; Mirzaei, H.R.; Jaafari, M.R. Therapeutic application of multipotent stem cells. J. Cell. Physiol., 2018, 233(4), 2815-2823.
[http://dx.doi.org/10.1002/jcp.25990] [PMID: 28475219]
[38]
Mirzaei, H.; Salehi, H.; Oskuee, R.K.; Mohammadpour, A.; Mirzaei, H.R.; Sharifi, M.R.; Salarinia, R.; Darani, H.Y.; Mokhtari, M.; Masoudifar, A.; Sahebkar, A.; Salehi, R.; Jaafari, M.R. The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model. Cancer Lett., 2018, 419, 30-39.
[http://dx.doi.org/10.1016/j.canlet.2018.01.029] [PMID: 29331419]
[39]
Mirzaei, H.; Shakeri, A.; Rashidi, B.; Jalili, A.; Banikazemi, Z.; Sahebkar, A. Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies. Biomed. Pharmacother., 2017, 85, 102-112.
[http://dx.doi.org/10.1016/j.biopha.2016.11.098] [PMID: 27930973]
[40]
Mirzaei, H.; Yazdi, F.; Salehi, R.; Mirzaei, H.R. SiRNA and epigenetic aberrations in ovarian cancer. J. Cancer Res. Ther., 2016, 12(2), 498-508.
[http://dx.doi.org/10.4103/0973-1482.153661] [PMID: 27461600]
[41]
Mirzaei, H.R.; Jamali, A.; Jafarzadeh, L.; Masoumi, E.; Alishah, K.; Fallah Mehrjardi, K.; Emami, S.A.H.; Noorbakhsh, F.; Till, B.G.; Hadjati, J. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells. J. Cell. Physiol., 2019, 234(6), 9207-9215.
[http://dx.doi.org/10.1002/jcp.27599] [PMID: 30362586]
[42]
Mirzaei, H.R.; Mirzaei, H.; Lee, S.Y.; Hadjati, J.; Till, B.G. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett., 2016, 380(2), 413-423.
[http://dx.doi.org/10.1016/j.canlet.2016.07.001] [PMID: 27392648]
[43]
Mirzaei, H.R.; Pourghadamyari, H.; Rahmati, M.; Mohammadi, A.; Nahand, J.S.; Rezaei, A.; Mirzaei, H.; Hadjati, J. Gene-knocked out chimeric antigen receptor (CAR) T cells: Tuning up for the next generation cancer immunotherapy. Cancer Lett., 2018, 423, 95-104.
[http://dx.doi.org/10.1016/j.canlet.2018.03.010] [PMID: 29544719]
[44]
Mirzaei, H.R.; Rodriguez, A.; Shepphird, J.; Brown, C.E.; Badie, B. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. Front. Immunol., 2017, 8, 1850.
[http://dx.doi.org/10.3389/fimmu.2017.01850] [PMID: 29312333]
[45]
Mirzaei, H.R.; Sahebkar, A.; Salehi, R.; Nahand, J.S.; Karimi, E.; Jaafari, M.R.; Mirzaei, H. Boron neutron capture therapy: Moving toward targeted cancer therapy. J. Cancer Res. Ther., 2016, 12(2), 520-525.
[http://dx.doi.org/10.4103/0973-1482.176167] [PMID: 27461603]
[46]
Mohammadi, M.; Jaafari, M.R.; Mirzaei, H.R.; Mirzaei, H. Mesenchymal stem cell: a new horizon in cancer gene therapy. Cancer Gene Ther., 2016, 23(9), 285-286.
[http://dx.doi.org/10.1038/cgt.2016.35] [PMID: 27650780]
[47]
Moradian Tehrani, R.; Verdi, J.; Noureddini, M.; Salehi, R.; Salarinia, R.; Mosalaei, M.; Simonian, M.; Alani, B.; Ghiasi, M.R.; Jaafari, M.R.; Mirzaei, H.R.; Mirzaei, H. Mesenchymal stem cells: A new platform for targeting suicide genes in cancer. J. Cell. Physiol., 2018, 233(5), 3831-3845.
[http://dx.doi.org/10.1002/jcp.26094] [PMID: 28703313]
[48]
Pourhanifeh, M.H.; Mohammadi, R.; Noruzi, S.; Hosseini, S.A.; Fanoudi, S.; Mohamadi, Y.; Hashemzehi, M.; Asemi, Z.; Mirzaei, H.R.; Salarinia, R.; Mirzaei, H. The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy. Cancer Cell Int., 2019, 19, 157.
[http://dx.doi.org/10.1186/s12935-019-0870-6] [PMID: 31198406]
[49]
Rashidi, B; Malekzadeh, M; Goodarzi, M; Masoudifar, A; Mirzaei, H Green tea and its anti-angiogenesis effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie , 2017, 89, 949-956.
[http://dx.doi.org/10.1016/j.biopha.2017.01.161]
[50]
Sadeghi, S.; Davoodvandi, A.; Pourhanifeh, M.H.; Sharifi, N.; ArefNezhad, R.; Sahebnasagh, R.; Moghadam, S.A.; Sahebkar, A.; Mirzaei, H. Anti-cancer effects of cinnamon: Insights into its apoptosis effects. Eur. J. Med. Chem., 2019, 178, 131-140.
[http://dx.doi.org/10.1016/j.ejmech.2019.05.067] [PMID: 31195168]
[51]
Tamtaji, O.R.; Mirzaei, H.; Shamshirian, A.; Shamshirian, D.; Behnam, M.; Asemi, Z. New trends in glioma cancer therapy: Targeting Na+/H + exchangers. J. Cell. Physiol., 2020, 235(2), 658-665.
[http://dx.doi.org/10.1002/jcp.29014] [PMID: 31250444]
[52]
Vakili-Ghartavol, R.; Mombeiny, R.; Salmaninejad, A.; Sorkhabadi, S.M.R.; Faridi-Majidi, R.; Jaafari, M.R.; Mirzaei, H. Tumor-associated macrophages and epithelial-mesenchymal transition in cancer: Nanotechnology comes into view. J. Cell. Physiol., 2018, 233(12), 9223-9236.
[http://dx.doi.org/10.1002/jcp.27027] [PMID: 30078227]
[53]
Shafabakhsh, R.; Pourhanifeh, M.H.; Mirzaei, H.R.; Sahebkar, A.; Asemi, Z.; Mirzaei, H. Targeting regulatory T cells by curcumin: A potential for cancer immunotherapy. Pharmacol. Res., 2019, 147104353
[http://dx.doi.org/10.1016/j.phrs.2019.104353] [PMID: 31306775]
[54]
Khan, H.; Mirzaei, H.R.; Amiri, A.; Kupeli Akkol, E.; Ashhad Halimi, S.M.; Mirzaei, H. Glyco-nanoparticles: New drug delivery systems in cancer therapy. Semin. Cancer Biol., 2019.S1044-579X(19)30400-6
[http://dx.doi.org/10.1016/j.semcancer.2019.12.004] [PMID: 31870939]
[55]
Salehi, M; Movahedpour, A; Tayarani, A; Shabaninejad, Z; Pourhanifeh, MH; Mortezapour, E; Nickdasti, A; Mottaghi, R; Davoodabadi, A; Khan, H Therapeutic potentials of curcumin in the treatment of non-small-cell lung carcinoma., 2020.
[http://dx.doi.org/10.1002/ptr.6704]
[56]
Alirezaei, Z.; Pourhanifeh, M.H.; Borran, S.; Nejati, M.; Mirzaei, H.; Hamblin, M.R. Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders. Mol. Neurobiol., 2020, 57(1), 469-491.
[http://dx.doi.org/10.1007/s12035-019-01698-3] [PMID: 31385229]
[57]
Jafari, S.H.; Saadatpour, Z.; Salmaninejad, A.; Momeni, F.; Mokhtari, M.; Nahand, J.S.; Rahmati, M.; Mirzaei, H.; Kianmehr, M. Breast cancer diagnosis: Imaging techniques and biochemical markers. J. Cell. Physiol., 2018, 233(7), 5200-5213.
[http://dx.doi.org/10.1002/jcp.26379] [PMID: 29219189]
[58]
Keshavarzi, M.; Darijani, M.; Momeni, F.; Moradi, P.; Ebrahimnejad, H.; Masoudifar, A.; Mirzaei, H. Molecular Imaging and Oral Cancer Diagnosis and Therapy. J. Cell. Biochem., 2017, 118(10), 3055-3060.
[http://dx.doi.org/10.1002/jcb.26042] [PMID: 28390191]
[59]
Keshavarzi, M.; Sorayayi, S.; Jafar Rezaei, M.; Mohammadi, M.; Ghaderi, A.; Rostamzadeh, A.; Masoudifar, A.; Mirzaei, H. MicroRNAs-Based Imaging Techniques in Cancer Diagnosis and Therapy. J. Cell. Biochem., 2017, 118(12), 4121-4128.
[http://dx.doi.org/10.1002/jcb.26012] [PMID: 28370207]
[60]
Mirzaei, H.R.; Mirzaei, H.; Namdar, A.; Rahmati, M.; Till, B.G.; Hadjati, J. Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: A clinical perspective. J. Cell. Physiol., 2019, 234(5), 5827-5841.
[http://dx.doi.org/10.1002/jcp.27519] [PMID: 30317583]
[61]
Momeni, F.; Ghaemmaghami, A.B.; Nejati, M.; Pourhanifeh, M.H.; Sichani, L.S.; Tamtaji, O.R.; Momeni, M.; Khosravi, A.; Etemadifar, M.; Mirzaei, H. Joint Application of Magnetic Resonance Imaging and Biochemical Biomarkers in Diagnosis of Multiple Sclerosis. Curr. Med. Chem., 2019.
[http://dx.doi.org/10.2174/0929867326666191014162713] [PMID: 31633472]
[62]
Saadatpour, Z.; Bjorklund, G.; Chirumbolo, S.; Alimohammadi, M.; Ehsani, H.; Ebrahiminejad, H.; Pourghadamyari, H.; Baghaei, B.; Mirzaei, H.R.; Sahebkar, A.; Mirzaei, H.; Keshavarzi, M. Molecular imaging and cancer gene therapy. Cancer Gene Ther., 2016.
[http://dx.doi.org/10.1038/cgt.2016.62] [PMID: 27857058]
[63]
Saadatpour, Z.; Rezaei, A.; Ebrahimnejad, H.; Baghaei, B.; Bjorklund, G.; Chartrand, M.; Sahebkar, A.; Morovati, H.; Mirzaei, H.R.; Mirzaei, H. Imaging techniques: new avenues in cancer gene and cell therapy. Cancer Gene Ther., 2017, 24(1), 1-5.
[http://dx.doi.org/10.1038/cgt.2016.61] [PMID: 27834357]
[64]
Boone, J.D.; Erickson, B.K.; Huh, W.K. New insights into cervical cancer screening. J. Gynecol. Oncol., 2012, 23(4), 282-287.
[http://dx.doi.org/10.3802/jgo.2012.23.4.282] [PMID: 23094132]
[65]
Nanda, K.; McCrory, D.C.; Myers, E.R.; Bastian, L.A.; Hasselblad, V.; Hickey, J.D.; Matchar, D.B. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med., 2000, 132(10), 810-819.
[http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00009] [PMID: 10819705]
[66]
Bourgioti, C.; Chatoupis, K.; Moulopoulos, L.A. Current imaging strategies for the evaluation of uterine cervical cancer. World J. Radiol., 2016, 8(4), 342-354.
[http://dx.doi.org/10.4329/wjr.v8.i4.342] [PMID: 27158421]
[67]
Patel, S.; Liyanage, S.H.; Sahdev, A.; Rockall, A.G.; Reznek, R.H. Imaging of endometrial and cervical cancer. Insights Imaging, 2010, 1(5-6), 309-328.
[http://dx.doi.org/10.1007/s13244-010-0042-7] [PMID: 22347925]
[68]
Kori, M.; Yalcin Arga, K. Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective. PLoS One, 2018, 13(7)e0200717
[http://dx.doi.org/10.1371/journal.pone.0200717] [PMID: 30020984]
[69]
Wang, S.; Chen, X. Identification of potential biomarkers in cervical cancer with combined public mRNA and miRNA expression microarray data analysis. Oncol. Lett., 2018, 16(4), 5200-5208.
[http://dx.doi.org/10.3892/ol.2018.9323] [PMID: 30250588]
[70]
Banikazemi, Z.; Haji, H.A.; Mohammadi, M.; Taheripak, G.; Iranifar, E.; Poursadeghiyan, M.; Moridikia, A.; Rashidi, B.; Taghizadeh, M.; Mirzaei, H. Diet and cancer prevention: Dietary compounds, dietary MicroRNAs, and dietary exosomes. J. Cell. Biochem., 2018, 119(1), 185-196.
[http://dx.doi.org/10.1002/jcb.26244] [PMID: 28657651]
[71]
Mirzaei, H.; Sahebkar, A.; Jaafari, M.R.; Goodarzi, M.; Mirzaei, H.R. Diagnostic and Therapeutic Potential of Exosomes in Cancer: The Beginning of a New Tale? J. Cell. Physiol., 2017, 232(12), 3251-3260.
[http://dx.doi.org/10.1002/jcp.25739] [PMID: 27966794]
[72]
Mohammadi, S.; Yousefi, F.; Shabaninejad, Z.; Movahedpour, A.; Mahjoubin Tehran, M.; Shafiee, A.; Moradizarmehri, S.; Hajighadimi, S.; Savardashtaki, A.; Mirzaei, H. Exosomes and cancer: From oncogenic roles to therapeutic applications. IUBMB Life, 2020, 72(4), 724-748.
[http://dx.doi.org/10.1002/iub.2182] [PMID: 31618516]
[73]
Saadatpour, L.; Fadaee, E.; Fadaei, S.; Nassiri Mansour, R.; Mohammadi, M.; Mousavi, S.M.; Goodarzi, M.; Verdi, J.; Mirzaei, H. Glioblastoma: exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Ther., 2016, 23(12), 415-418.
[http://dx.doi.org/10.1038/cgt.2016.48] [PMID: 27834360]
[74]
Sadri Nahand, J.; Moghoofei, M.; Salmaninejad, A.; Bahmanpour, Z.; Karimzadeh, M.; Nasiri, M.; Mirzaei, H.R.; Pourhanifeh, M.H.; Bokharaei-Salim, F.; Mirzaei, H.; Hamblin, M.R. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review. Int. J. Cancer, 2020, 146(2), 305-320.
[http://dx.doi.org/10.1002/ijc.32688] [PMID: 31566705]
[75]
Tavakolizadeh, J.; Roshanaei, K.; Salmaninejad, A.; Yari, R.; Nahand, J.S.; Sarkarizi, H.K.; Mousavi, S.M.; Salarinia, R.; Rahmati, M.; Mousavi, S.F.; Mokhtari, R.; Mirzaei, H. MicroRNAs and exosomes in depression: Potential diagnostic biomarkers. J. Cell. Biochem., 2018, 119(5), 3783-3797.
[http://dx.doi.org/10.1002/jcb.26599] [PMID: 29236313]
[76]
Pecorelli, S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet., 2009, 105(2), 103-104.
[http://dx.doi.org/10.1016/j.ijgo.2009.02.012] [PMID: 19367689]
[77]
Pecorelli, S.; Zigliani, L.; Odicino, F. Revised FIGO staging for carcinoma of the cervix. Int. J. Gynaecol. Obstet., 2009, 105(2), 107-108.
[http://dx.doi.org/10.1016/j.ijgo.2009.02.009] [PMID: 19342051]
[78]
Bhosale, P.; Peungjesada, S.; Devine, C.; Balachandran, A.; Iyer, R. Role of magnetic resonance imaging as an adjunct to clinical staging in cervical carcinoma. J. Comput. Assist. Tomogr., 2010, 34(6), 855-864.
[http://dx.doi.org/10.1097/RCT.0b013e3181ed3090] [PMID: 21084900]
[79]
Mirpour, S.; Mhlanga, J.C.; Logeswaran, P.; Russo, G.; Mercier, G.; Subramaniam, R.M. The role of PET/CT in the management of cervical cancer. AJR Am. J. Roentgenol., 2013, 201(2)W192-205
[http://dx.doi.org/10.2214/AJR.12.9830] [PMID: 23883234]
[80]
Grigsby, P.W. The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging, 2008, 8(1), 146-155.
[http://dx.doi.org/10.1102/1470-7330.2008.0022] [PMID: 18694852]
[81]
Romesser, P.B.; Qureshi, M.M.; Shah, B.A.; Chatburn, L.T.; Jalisi, S.; Devaiah, A.K.; Subramaniam, R.M.; Truong, M.T. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann. Nucl. Med., 2012, 26(7), 527-534.
[http://dx.doi.org/10.1007/s12149-012-0604-5] [PMID: 22610386]
[82]
Eschmann, S.M.; Friedel, G.; Paulsen, F.; Reimold, M.; Hehr, T.; Budach, W.; Scheiderbauer, J.; Machulla, H.J.; Dittmann, H.; Vonthein, R.; Bares, R. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur. J. Nucl. Med. Mol. Imaging, 2006, 33(3), 263-269.
[http://dx.doi.org/10.1007/s00259-005-1953-2] [PMID: 16270214]
[83]
Kidd, E.A.; Siegel, B.A.; Dehdashti, F.; Grigsby, P.W. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer, 2007, 110(8), 1738-1744.
[http://dx.doi.org/10.1002/cncr.22974] [PMID: 17786947]
[84]
Havrilesky, L.J.; Kulasingam, S.L.; Matchar, D.B.; Myers, E.R. FDG-PET for management of cervical and ovarian cancer. Gynecol. Oncol., 2005, 97(1), 183-191.
[http://dx.doi.org/10.1016/j.ygyno.2004.12.007] [PMID: 15790456]
[85]
Ryu, SY; Kim, MH; Choi, SC; Choi, CW; Lee, KH Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2003, 44(3), 347-352.
[86]
Son, H.; Kositwattanarerk, A.; Hayes, M.P.; Chuang, L.; Rahaman, J.; Heiba, S.; Machac, J.; Zakashansky, K.; Kostakoglu, L. PET/CT evaluation of cervical cancer: spectrum of disease. Radiographics, 2010, 30(5), 1251-1268.
[http://dx.doi.org/10.1148/rg.305105703] [PMID: 20833849]
[87]
deSouza, N.M.; Dina, R.; McIndoe, G.A.; Soutter, W.P. Cervical cancer: value of an endovaginal coil magnetic resonance imaging technique in detecting small volume disease and assessing parametrial extension. Gynecol. Oncol., 2006, 102(1), 80-85.
[http://dx.doi.org/10.1016/j.ygyno.2005.11.038] [PMID: 16427688]
[88]
Sala, E.; Rockall, A.G.; Freeman, S.J.; Mitchell, D.G.; Reinhold, C. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. Radiology, 2013, 266(3), 717-740.
[http://dx.doi.org/10.1148/radiol.12120315] [PMID: 23431227]
[89]
Sala, E.; Wakely, S.; Senior, E.; Lomas, D. MRI of malignant neoplasms of the uterine corpus and cervix. AJR Am. J. Roentgenol., 2007, 188(6), 1577-1587.
[http://dx.doi.org/10.2214/AJR.06.1196] [PMID: 17515380]
[90]
Chung, H.H.; Kang, S.B.; Cho, J.Y.; Kim, J.W.; Park, N.H.; Song, Y.S.; Kim, S.H.; Lee, H.P. Can preoperative MRI accurately evaluate nodal and parametrial invasion in early stage cervical cancer? Jpn. J. Clin. Oncol., 2007, 37(5), 370-375.
[http://dx.doi.org/10.1093/jjco/hym036] [PMID: 17556538]
[91]
Leach, M.O.; Brindle, K.M.; Evelhoch, J.L.; Griffiths, J.R.; Horsman, M.R.; Jackson, A.; Jayson, G.C.; Judson, I.R.; Knopp, M.V.; Maxwell, R.J.; McIntyre, D.; Padhani, A.R.; Price, P.; Rathbone, R.; Rustin, G.J.; Tofts, P.S.; Tozer, G.M.; Vennart, W.; Waterton, J.C.; Williams, S.R.; Workman, P. Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br. J. Cancer, 2005, 92(9), 1599-1610.
[http://dx.doi.org/10.1038/sj.bjc.6602550] [PMID: 15870830]
[92]
Funt, S.A.; Hricak, H. Ovarian malignancies. Top. Magn. Reson. Imaging, 2003, 14(4), 329-337.
[http://dx.doi.org/10.1097/00002142-200308000-00005] [PMID: 14578777]
[93]
Harry, V.N.; Semple, S.I.; Gilbert, F.J.; Parkin, D.E. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol. Oncol., 2008, 111(2), 213-220.
[http://dx.doi.org/10.1016/j.ygyno.2008.07.048] [PMID: 18774597]
[94]
Follen, M.; Levenback, C.F.; Iyer, R.B.; Grigsby, P.W.; Boss, E.A.; Delpassand, E.S.; Fornage, B.D.; Fishman, E.K. Imaging in cervical cancer. Cancer, 2003, 98(9)(Suppl.), 2028-2038.
[http://dx.doi.org/10.1002/cncr.11679] [PMID: 14603539]
[95]
Sun, L.T.; Ning, C.P.; Liu, Y.J.; Wang, Z.Z.; Wang, L.D.; Kong, X.C.; Tian, J.W. Is transvaginal elastography useful in pre-operative diagnosis of cervical cancer? Eur. J. Radiol., 2012, 81(8), e888-e892.
[http://dx.doi.org/10.1016/j.ejrad.2012.04.025] [PMID: 22717123]
[96]
Fischerova, D; Cibula, D; Stenhova, H; Vondrichova, H; Calda, P; Zikan, M; Freitag, P; Slama, J; Dundr, P; Belacek, J Transrectal ultrasound and magnetic resonance imaging in staging of early cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2008, 18(4), 766-772.
[http://dx.doi.org/10.1111/j.1525-1438.2007.01072.x]
[97]
Unger, J.B.; Ivy, J.J.; Connor, P.; Charrier, A.; Ramaswamy, M.R.; Ampil, F.L.; Monsour, R.P. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecol. Oncol., 2004, 94(1), 212-216.
[http://dx.doi.org/10.1016/j.ygyno.2004.04.021] [PMID: 15262145]
[98]
Hricak, H.; Gatsonis, C.; Chi, D.S.; Amendola, M.A.; Brandt, K.; Schwartz, L.H.; Koelliker, S.; Siegelman, E.S.; Brown, J.J.; McGhee, R.B., Jr; Iyer, R.; Vitellas, K.M.; Snyder, B.; Long, H.J., III; Fiorica, J.V.; Mitchell, D.G. American College of Radiology Imaging Network 6651; Gynecologic Oncology Group 183. Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J. Clin. Oncol., 2005, 23(36), 9329-9337.
[http://dx.doi.org/10.1200/JCO.2005.02.0354] [PMID: 16361632]
[99]
Sironi, S.; Buda, A.; Picchio, M.; Perego, P.; Moreni, R.; Pellegrino, A.; Colombo, M.; Mangioni, C.; Messa, C.; Fazio, F. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology, 2006, 238(1), 272-279.
[http://dx.doi.org/10.1148/radiol.2381041799] [PMID: 16304090]
[100]
Hricak, H.; Gatsonis, C.; Coakley, F.V.; Snyder, B.; Reinhold, C.; Schwartz, L.H.; Woodward, P.J.; Pannu, H.K.; Amendola, M.; Mitchell, D.G. Early invasive cervical cancer: CT and MR imaging in preoperative evaluation - ACRIN/GOG comparative study of diagnostic performance and interobserver variability. Radiology, 2007, 245(2), 491-498.
[http://dx.doi.org/10.1148/radiol.2452061983] [PMID: 17940305]
[101]
Shweel, M.A.; Abdel-Gawad, E.A.; Abdel-Gawad, E.A.; Abdelghany, H.S.; Abdel-Rahman, A.M.; Ibrahim, E.M. Uterine cervical malignancy: diagnostic accuracy of MRI with histopathologic correlation. J. Clin. Imaging Sci., 2012, 2, 42.
[http://dx.doi.org/10.4103/2156-7514.99175] [PMID: 22919556]
[102]
Grueneisen, J.; Schaarschmidt, B.M.; Heubner, M.; Aktas, B.; Kinner, S.; Forsting, M.; Lauenstein, T.; Ruhlmann, V.; Umutlu, L. Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. Eur. J. Nucl. Med. Mol. Imaging, 2015, 42(12), 1814-1824.
[http://dx.doi.org/10.1007/s00259-015-3131-5] [PMID: 26199113]
[103]
Downey, K.; Attygalle, A.D.; Morgan, V.A.; Giles, S.L.; MacDonald, A.; Davis, M.; Ind, T.E.; Shepherd, J.H.; deSouza, N.M. Comparison of optimised endovaginal vs external array coil T2-weighted and diffusion-weighted imaging techniques for detecting suspected early stage (IA/IB1) uterine cervical cancer. Eur. Radiol., 2016, 26(4), 941-950.
[http://dx.doi.org/10.1007/s00330-015-3899-5] [PMID: 26162579]
[104]
Bhosale, P.R.; Iyer, R.B.; Ramalingam, P.; Schmeler, K.M.; Wei, W.; Bassett, R.L.; Ramirez, P.T.; Frumovitz, M. Is MRI helpful in assessing the distance of the tumour from the internal os in patients with cervical cancer below FIGO Stage IB2? Clin. Radiol., 2016, 71(6), 515-522.
[http://dx.doi.org/10.1016/j.crad.2016.02.009] [PMID: 27012496]
[105]
Jung, W.; Park, K.R.; Lee, K.J.; Kim, K.; Lee, J.; Jeong, S.; Kim, Y.J.; Kim, J.; Yoon, H.J.; Kang, B.C.; Koo, H.S.; Sung, S.H.; Cho, M.S.; Park, S. Value of imaging study in predicting pelvic lymph node metastases of uterine cervical cancer. Radiat. Oncol. J., 2017, 35(4), 340-348.
[http://dx.doi.org/10.3857/roj.2017.00206] [PMID: 29232805]
[106]
Tanaka, T.; Sasaki, S.; Tsuchihashi, H.; Terai, Y.; Yamamoto, K.; Yamada, T.; Ohmichi, M. Which is better for predicting pelvic lymph node metastases in patients with cervical cancer: Fluorodeoxyglucose-positron emission tomography/computed tomography or a sentinel node biopsy? A retrospective observational study. Medicine (Baltimore), 2018, 97(16)e0410
[http://dx.doi.org/10.1097/MD.0000000000010410] [PMID: 29668599]
[107]
Wentzensen, N.; von Knebel Doeberitz, M. Biomarkers in cervical cancer screening. Dis. Markers, 2007, 23(4), 315-330.
[http://dx.doi.org/10.1155/2007/678793] [PMID: 17627065]
[108]
Sahasrabuddhe, V.V.; Luhn, P.; Wentzensen, N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol., 2011, 6(9), 1083-1098.
[http://dx.doi.org/10.2217/fmb.11.87] [PMID: 21958146]
[109]
Garland, S.M. Can cervical cancer be eradicated by prophylactic HPV vaccination? Challenges to vaccine implementation. Indian J. Med. Res., 2009, 130(3), 311-321.
[PMID: 19901440]
[110]
McGraw, S.L.; Ferrante, J.M. Update on prevention and screening of cervical cancer. World J. Clin. Oncol., 2014, 5(4), 744-752.
[http://dx.doi.org/10.5306/wjco.v5.i4.744] [PMID: 25302174]
[111]
Solomon, D.; Davey, D.; Kurman, R.; Moriarty, A.; O’Connor, D.; Prey, M.; Raab, S.; Sherman, M.; Wilbur, D.; Wright, T., Jr; Young, N. Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA, 2002, 287(16), 2114-2119.
[http://dx.doi.org/10.1001/jama.287.16.2114] [PMID: 11966386]
[112]
Rodríguez, A.C.; Schiffman, M.; Herrero, R.; Wacholder, S.; Hildesheim, A.; Castle, P.E.; Solomon, D.; Burk, R. Proyecto Epidemiológico Guanacaste Group. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J. Natl. Cancer Inst., 2008, 100(7), 513-517.
[http://dx.doi.org/10.1093/jnci/djn044] [PMID: 18364507]
[113]
Wright, T.C., Jr; Schiffman, M.; Solomon, D.; Cox, J.T.; Garcia, F.; Goldie, S.; Hatch, K.; Noller, K.L.; Roach, N.; Runowicz, C.; Saslow, D. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet. Gynecol., 2004, 103(2), 304-309.
[http://dx.doi.org/10.1097/01.AOG.0000109426.82624.f8] [PMID: 14754700]
[114]
Cuzick, J.; Szarewski, A.; Cubie, H.; Hulman, G.; Kitchener, H.; Luesley, D.; McGoogan, E.; Menon, U.; Terry, G.; Edwards, R.; Brooks, C.; Desai, M.; Gie, C.; Ho, L.; Jacobs, I.; Pickles, C.; Sasieni, P. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet, 2003, 362(9399), 1871-1876.
[http://dx.doi.org/10.1016/S0140-6736(03)14955-0] [PMID: 14667741]
[115]
Cuzick, J.; Mayrand, M.H.; Ronco, G.; Snijders, P.; Wardle, J. Chapter 10: New dimensions in cervical cancer screeningVaccine ; , 2006, 3, p. (24 Suppl)S3/90-97.
[116]
zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer, 2002, 2(5), 342-350.
[http://dx.doi.org/10.1038/nrc798] [PMID: 12044010]
[117]
von Knebel Doeberitz, M New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. European journal of cancer (Oxford, England : 1990), 2002, 38(17), 2229-2242.
[http://dx.doi.org/10.1016/S0959-8049(02)00462-8]
[118]
Klaes, R.; Benner, A.; Friedrich, T.; Ridder, R.; Herrington, S.; Jenkins, D.; Kurman, R.J.; Schmidt, D.; Stoler, M.; von Knebel Doeberitz, M. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am. J. Surg. Pathol., 2002, 26(11), 1389-1399.
[http://dx.doi.org/10.1097/00000478-200211000-00001] [PMID: 12409715]
[119]
Wang, S.S.; Trunk, M.; Schiffman, M.; Herrero, R.; Sherman, M.E.; Burk, R.D.; Hildesheim, A.; Bratti, M.C.; Wright, T.; Rodriguez, A.C.; Chen, S.; Reichert, A.; von Knebel Doeberitz, C.; Ridder, R.; von Knebel Doeberitz, M. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol. Biomarkers Prev., 2004, 13(8), 1355-1360.
[PMID: 15298958]
[120]
Trunk, M.J.; Dallenbach-Hellweg, G.; Ridder, R.; Petry, K.U.; Ikenberg, H.; Schneider, V.; von Knebel Doeberitz, M. Morphologic characteristics of p16INK4a-positive cells in cervical cytology samples. Acta Cytol., 2004, 48(6), 771-782.
[http://dx.doi.org/10.1159/000326445] [PMID: 15581161]
[121]
Wentzensen, N.; Bergeron, C.; Cas, F.; Eschenbach, D.; Vinokurova, S.; von Knebel Doeberitz, M. Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer, 2005, 105(6), 461-467.
[http://dx.doi.org/10.1002/cncr.21378] [PMID: 16116604]
[122]
Carozzi, F.; Cecchini, S.; Confortini, M.; Becattini, V.; Cariaggi, M.P.; Pontenani, G.; Sani, C.; Ciatto, S. Role of P16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. Cancer, 2006, 108(2), 119-123.
[http://dx.doi.org/10.1002/cncr.21713] [PMID: 16411180]
[123]
Wentzensen, N.; Hampl, M.; Herkert, M.; Reichert, A.; Trunk, M.J.; Poremba, C.; Ridder, R.; von Knebel Doeberitz, M. Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples. Cancer, 2006, 107(9), 2307-2313.
[http://dx.doi.org/10.1002/cncr.22247] [PMID: 17029280]
[124]
Shroyer, K.R.; Homer, P.; Heinz, D.; Singh, M. Validation of a novel immunocytochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression in cervical cytology. Cancer, 2006, 108(5), 324-330.
[http://dx.doi.org/10.1002/cncr.22171] [PMID: 16937378]
[125]
Guo, M.; Baruch, A.C.; Silva, E.G.; Jan, Y.J.; Lin, E.; Sneige, N.; Deavers, M.T. Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma. Am. J. Clin. Pathol., 2011, 135(2), 212-220.
[http://dx.doi.org/10.1309/AJCP1LLX8QMDXHHO] [PMID: 21228361]
[126]
Murphy, N.; Ring, M.; Heffron, C.C.; King, B.; Killalea, A.G.; Hughes, C.; Martin, C.M.; McGuinness, E.; Sheils, O.; O’Leary, J.J. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J. Clin. Pathol., 2005, 58(5), 525-534.
[http://dx.doi.org/10.1136/jcp.2004.018895] [PMID: 15858126]
[127]
Kruse, A-J.; Baak, J.P.A.; Helliesen, T.; Kjellevold, K.H.; Bol, M.G.W.; Janssen, E.A.M. Evaluation of MIB-1-positive cell clusters as a diagnostic marker for cervical intraepithelial neoplasia. Am. J. Surg. Pathol., 2002, 26(11), 1501-1507.
[http://dx.doi.org/10.1097/00000478-200211000-00013] [PMID: 12409727]
[128]
Luttmer, R.; Dijkstra, M.G.; Snijders, P.J.; Berkhof, J.; van Kemenade, F.J.; Rozendaal, L.; Helmerhorst, T.J.; Verheijen, R.H.; Ter Harmsel, W.A.; van Baal, W.M. p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Modern pathology: an official journal of the United States and Canadian Academy of Pathology. Inc, 2016, 29(8), 870-878.
[129]
Zacapala-Gómez, A.E.; Navarro-Tito, N.; Alarcón-Romero, L.D.C.; Ortuño-Pineda, C.; Illades-Aguiar, B.; Castañeda-Saucedo, E.; Ortiz-Ortiz, J.; Garibay-Cerdenares, O.L.; Jiménez-López, M.A.; Mendoza-Catalán, M.A. Ezrin and E-cadherin expression profile in cervical cytology: a prognostic marker for tumor progression in cervical cancer. BMC Cancer, 2018, 18(1), 349.
[http://dx.doi.org/10.1186/s12885-018-4243-7] [PMID: 29587669]
[130]
Del Pino, M.; Svanholm-Barrie, C.; Torné, A.; Marimon, L.; Gaber, J.; Sagasta, A.; Persing, D.H.; Ordi, J. mRNA biomarker detection in liquid-based cytology: a new approach in the prevention of cervical cancer. Modern pathology: an official journal of the United States and Canadian Academy of Pathology. Inc, 2015, 28(2), 312-320.
[131]
Jafari Najaf Abadi, M.H.; Shafabakhsh, R.; Asemi, Z.; Mirzaei, H.R.; Sahebnasagh, R.; Mirzaei, H.; Hamblin, M.R. CFIm25 and alternative polyadenylation: Conflicting roles in cancer. Cancer Lett., 2019, 459, 112-121.
[http://dx.doi.org/10.1016/j.canlet.2019.114430] [PMID: 31181319]
[132]
Shabaninejad, Z.; Vafadar, A.; Movahedpour, A.; Ghasemi, Y.; Namdar, A.; Fathizadeh, H.; Pourhanifeh, M.H.; Savardashtaki, A.; Mirzaei, H. Circular RNAs in cancer: new insights into functions and implications in ovarian cancer. J. Ovarian Res., 2019, 12(1), 84.
[http://dx.doi.org/10.1186/s13048-019-0558-5] [PMID: 31481095]
[133]
Shabaninejad, Z.; Yousefi, F.; Movahedpour, A.; Ghasemi, Y.; Dokanehiifard, S.; Rezaei, S.; Aryan, R.; Savardashtaki, A.; Mirzaei, H. Electrochemical-based biosensors for microRNA detection: Nanotechnology comes into view. Anal. Biochem., 2019, 581113349
[http://dx.doi.org/10.1016/j.ab.2019.113349] [PMID: 31254490]
[134]
Vafadar, A.; Shabaninejad, Z.; Movahedpour, A.; Mohammadi, S.; Fathullahzadeh, S.; Mirzaei, H.R.; Namdar, A.; Savardashtaki, A.; Mirzaei, H. Long Non-Coding RNAs As Epigenetic Regulators in Cancer. Curr. Pharm. Des., 2019, 25(33), 3563-3577.
[http://dx.doi.org/10.2174/1381612825666190830161528] [PMID: 31470781]
[135]
Jamali, Z; Taheri-Anganeh, M; Shabaninejad, Z; Keshavarzi, A; Taghizadeh, H; Razavi, ZS; Mottaghi, R; Abolhassan, M; Movahedpour, A; Mirzaei, H Autophagy regulation by microRNAs: Novel insights into osteosarcoma therapy., 2020.
[136]
Nahand, JS; Mahjoubin-Tehran, M; Moghoofei, M; Pourhanifeh, MH; Mirzaei, HR; Asemi, Z; Khatami, A; Bokharaei-Salim, F; Mirzaei, H; Hamblin, MR Exosomal miRNAs: novel players in viral infection., 2020, 12(4), 353-370.
[http://dx.doi.org/10.2217/epi-2019-0192]
[137]
Naeli, P.; Pourhanifeh, M.H.; Karimzadeh, M.R.; Shabaninejad, Z.; Movahedpour, A.; Tarrahimofrad, H.; Mirzaei, H.R.; Bafrani, H.H.; Savardashtaki, A.; Mirzaei, H.; Hamblin, M.R. Circular RNAs and gastrointestinal cancers: Epigenetic regulators with a prognostic and therapeutic role. Crit. Rev. Oncol. Hematol., 2020, 145102854
[http://dx.doi.org/10.1016/j.critrevonc.2019.102854] [PMID: 31877535]
[138]
Sadri Nahand, J; Bokharaei-Salim, F; Karimzadeh, M; Moghoofei, M; Karampoor, S; Mirzaei, HR; Tabibzadeh, A; Jafari, A; Ghaderi, A; Asemi, Z MicroRNAs and exosomes: key players in HIV pathogenesis., 2020, 21(4), 246-278.
[http://dx.doi.org/10.1111/hiv.12822]
[139]
Savardashtaki, A; Shabaninejad, Z; Movahedpour, A; Sahebnasagh, R; Mirzaei, H; Hamblin, MR miRNAs derived from cancer-associated fibroblasts in colorectal cancer., 11(14), 1627-1645.2019,
[140]
Gholamin, S.; Mirzaei, H.; Razavi, S.M.; Hassanian, S.M.; Saadatpour, L.; Masoudifar, A.; ShahidSales, S.; Avan, A. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. J. Cell. Physiol., 2018, 233(2), 866-879.
[http://dx.doi.org/10.1002/jcp.25793] [PMID: 28145567]
[141]
Keshavarz, M.; Mirzaei, H.; Salemi, M.; Momeni, F.; Mousavi, M.J.; Sadeghalvad, M.; Arjeini, Y.; Solaymani-Mohammadi, F.; Sadri Nahand, J.; Namdari, H.; Mokhtari-Azad, T.; Rezaei, F. Influenza vaccine: Where are we and where do we go? Rev. Med. Virol., 2019, 29(1)e2014
[http://dx.doi.org/10.1002/rmv.2014] [PMID: 30408280]
[142]
Khani, P.; Nasri, F.; Khani Chamani, F.; Saeidi, F.; Sadri Nahand, J.; Tabibkhooei, A.; Mirzaei, H. Genetic and epigenetic contribution to astrocytic gliomas pathogenesis. J. Neurochem., 2019, 148(2), 188-203.
[http://dx.doi.org/10.1111/jnc.14616] [PMID: 30347482]
[143]
Mirzaei, H.; Ferns, G.A.; Avan, A.; Mobarhan, M.G. Cytokines and MicroRNA in Coronary Artery Disease. Adv. Clin. Chem., 2017, 82, 47-70.
[http://dx.doi.org/10.1016/bs.acc.2017.06.004] [PMID: 28939213]
[144]
Pakshir, K.; Badali, H.; Nami, S.; Mirzaei, H.; Ebrahimzadeh, V.; Morovati, H. Interactions between immune response to fungal infection and microRNAs: The pioneer tuners. Mycoses, 2020, 63(1), 4-20.
[http://dx.doi.org/10.1111/myc.13017] [PMID: 31597205]
[145]
Rabieian, R.; Boshtam, M.; Zareei, M.; Kouhpayeh, S.; Masoudifar, A.; Mirzaei, H. Plasminogen Activator Inhibitor Type-1 as a Regulator of Fibrosis. J. Cell. Biochem., 2018, 119(1), 17-27.
[http://dx.doi.org/10.1002/jcb.26146] [PMID: 28520219]
[146]
Saeedi Borujeni, M.J.; Esfandiary, E.; Baradaran, A.; Valiani, A.; Ghanadian, M.; Codoñer-Franch, P.; Basirat, R.; Alonso-Iglesias, E.; Mirzaei, H.; Yazdani, A. Molecular aspects of pancreatic β-cell dysfunction: Oxidative stress, microRNA, and long noncoding RNA. J. Cell. Physiol., 2019, 234(6), 8411-8425.
[http://dx.doi.org/10.1002/jcp.27755] [PMID: 30565679]
[147]
Rezaei, S.; Mahjoubin-Tehran, M.; Aghaee-Bakhtiari, S.H.; Jalili, A.; Movahedpour, A.; Khan, H.; Moghoofei, M.; Shojaei, Z.; R Hamblin, M.; Mirzaei, H. Autophagy-related MicroRNAs in chronic lung diseases and lung cancer. Crit. Rev. Oncol. Hematol., 2020, 153103063
[http://dx.doi.org/10.1016/j.critrevonc.2020.103063] [PMID: 32712519]
[148]
Hoseini, Z.; Sepahvand, F.; Rashidi, B.; Sahebkar, A.; Masoudifar, A.; Mirzaei, H. NLRP3 inflammasome: Its regulation and involvement in atherosclerosis. J. Cell. Physiol., 2018, 233(3), 2116-2132.
[http://dx.doi.org/10.1002/jcp.25930] [PMID: 28345767]
[149]
Jamali, L.; Tofigh, R.; Tutunchi, S.; Panahi, G.; Borhani, F.; Akhavan, S.; Nourmohammadi, P.; Ghaderian, S.M.H.; Rasouli, M.; Mirzaei, H. Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers. J. Cell. Physiol., 2018, 233(11), 8538-8550.
[http://dx.doi.org/10.1002/jcp.26850] [PMID: 29923196]
[150]
Mirzaei, H. Stroke in Women: Risk Factors and Clinical Biomarkers. J. Cell. Biochem., 2017, 118(12), 4191-4202.
[http://dx.doi.org/10.1002/jcb.26130] [PMID: 28498508]
[151]
Mirzaei, H.; Momeni, F.; Saadatpour, L.; Sahebkar, A.; Goodarzi, M.; Masoudifar, A.; Kouhpayeh, S.; Salehi, H.; Mirzaei, H.R.; Jaafari, M.R. MicroRNA: Relevance to stroke diagnosis, prognosis, and therapy. J. Cell. Physiol., 2018, 233(2), 856-865.
[http://dx.doi.org/10.1002/jcp.25787] [PMID: 28067403]
[152]
Rashidi, B.; Hoseini, Z.; Sahebkar, A.; Mirzaei, H. Anti-Atherosclerotic Effects of Vitamins D and E in Suppression of Atherogenesis. J. Cell. Physiol., 2017, 232(11), 2968-2976.
[http://dx.doi.org/10.1002/jcp.25738] [PMID: 27966778]
[153]
Simonian, M.; Mosallayi, M.; Mirzaei, H. Circulating miR-21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker. J. Cancer Res. Ther., 2018, 14(2), 475.
[PMID: 29516946]
[154]
Fathullahzadeh, S.; Mirzaei, H.; Honardoost, M.A.; Sahebkar, A.; Salehi, M. Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Ther., 2016, 23(10), 327-332.
[http://dx.doi.org/10.1038/cgt.2016.34] [PMID: 27659777]
[155]
Golabchi, K.; Soleimani-Jelodar, R.; Aghadoost, N.; Momeni, F.; Moridikia, A.; Nahand, J.S.; Masoudifar, A.; Razmjoo, H.; Mirzaei, H. MicroRNAs in retinoblastoma: Potential diagnostic and therapeutic biomarkers. J. Cell. Physiol., 2018, 233(4), 3016-3023.
[http://dx.doi.org/10.1002/jcp.26070] [PMID: 28657205]
[156]
Javandoost, E.; Firoozi-Majd, E.; Rostamian, H.; Khakpoor-Koosheh, M.; Mirzaei, H.R. Role of microRNAs in Chronic Lymphocytic Leukemia Pathogenesis. Curr. Med. Chem., 2020, 27(2), 282-297.
[http://dx.doi.org/10.2174/0929867326666190911114842] [PMID: 31544709]
[157]
Masoudi, M.S.; Mehrabian, E.; Mirzaei, H. MiR-21: A key player in glioblastoma pathogenesis. J. Cell. Biochem., 2018, 119(2), 1285-1290.
[http://dx.doi.org/10.1002/jcb.26300] [PMID: 28727188]
[158]
Mirzaei, H.; Fathullahzadeh, S.; Khanmohammadi, R.; Darijani, M.; Momeni, F.; Masoudifar, A.; Goodarzi, M.; Mardanshah, O.; Stenvang, J.; Jaafari, M.R.; Mirzaei, H.R. State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia. J. Cell. Physiol., 2018, 233(2), 888-900.
[http://dx.doi.org/10.1002/jcp.25799] [PMID: 28084621]
[159]
Mirzaei, H; Gholamin, S; Shahidsales, S; Sahebkar, A; Jaafari, MR; Mirzaei, HR; Hassanian, SM; Avan, A MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma., European journal of cancer (Oxford, England : 1990), 2016, 53, 25-32.
[http://dx.doi.org/10.1016/j.ejca.2015.10.009]
[160]
Mirzaei, H.; Khataminfar, S.; Mohammadparast, S.; Sales, S.S.; Maftouh, M.; Mohammadi, M.; Simonian, M.; Parizadeh, S.M.; Hassanian, S.M.; Avan, A. Circulating microRNAs as Potential Diagnostic Biomarkers and Therapeutic Targets in Gastric Cancer: Current Status and Future Perspectives. Curr. Med. Chem., 2016, 23(36), 4135-4150.
[http://dx.doi.org/10.2174/0929867323666160818093854] [PMID: 27538692]
[161]
Mirzaei, H.; Masoudifar, A.; Sahebkar, A.; Zare, N.; Sadri Nahand, J.; Rashidi, B.; Mehrabian, E.; Mohammadi, M.; Mirzaei, H.R.; Jaafari, M.R. MicroRNA: A novel target of curcumin in cancer therapy. J. Cell. Physiol., 2018, 233(4), 3004-3015.
[http://dx.doi.org/10.1002/jcp.26055] [PMID: 28617957]
[162]
Mirzaei, H.R.; Sahebkar, A.; Mohammadi, M.; Yari, R.; Salehi, H.; Jafari, M.H.; Namdar, A.; Khabazian, E.; Jaafari, M.R.; Mirzaei, H. Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers. Curr. Pharm. Des., 2016, 22(34), 5257-5269.
[http://dx.doi.org/10.2174/1381612822666160303110838] [PMID: 26935703]
[163]
Mohammadi, M.; Goodarzi, M.; Jaafari, M.R.; Mirzaei, H.R.; Mirzaei, H. Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma. Cancer Gene Ther., 2016, 23(11), 371-372.
[http://dx.doi.org/10.1038/cgt.2016.45] [PMID: 27740613]
[164]
Moridikia, A.; Mirzaei, H.; Sahebkar, A.; Salimian, J. MicroRNAs: Potential candidates for diagnosis and treatment of colorectal cancer. J. Cell. Physiol., 2018, 233(2), 901-913.
[http://dx.doi.org/10.1002/jcp.25801] [PMID: 28092102]
[165]
Naeli, P.; Yousefi, F.; Ghasemi, Y.; Savardashtaki, A.; Mirzaei, H. The Role of MicroRNAs in Lung Cancer: Implications for Diagnosis and Therapy. Curr. Mol. Med., 2020, 20(2), 90-101.
[http://dx.doi.org/10.2174/1566524019666191001113511] [PMID: 31573883]
[166]
Shen, S.N.; Wang, L.F.; Jia, Y.F.; Hao, Y.Q.; Zhang, L.; Wang, H. Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer. Diagn. Pathol., 2013, 8, 69.
[http://dx.doi.org/10.1186/1746-1596-8-69] [PMID: 23631806]
[167]
Wang, X.; Tang, S.; Le, S.Y.; Lu, R.; Rader, J.S.; Meyers, C.; Zheng, Z.M. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One, 2008, 3(7)e2557
[http://dx.doi.org/10.1371/journal.pone.0002557] [PMID: 18596939]
[168]
Xu, J.; Li, Y.; Wang, F.; Wang, X.; Cheng, B.; Ye, F.; Xie, X.; Zhou, C.; Lu, W. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene, 2013, 32(8), 976-987.
[http://dx.doi.org/10.1038/onc.2012.121] [PMID: 22469983]
[169]
Li, C.; Zheng, X.; Li, W.; Bai, F.; Lyu, J.; Meng, Q.H. Serum miR-486-5p as a diagnostic marker in cervical cancer: with investigation of potential mechanisms. BMC Cancer, 2018, 18(1), 61.
[http://dx.doi.org/10.1186/s12885-017-3753-z] [PMID: 29316891]
[170]
Guo, H.; Yang, S.; Xu, L.; Li, D.; Tang, J.; Wang, S.; Wei, B.; Liu, Z. Association between the p73 gene G4C14-to-A4T14 single nucleotide polymorphism and risk of cervical cancer by high resolution melting and PCR with confronting two-pair primers in a Chinese population. Oncol. Lett., 2016, 12(1), 721-726.
[http://dx.doi.org/10.3892/ol.2016.4655] [PMID: 27347206]
[171]
Wang, S.; Wu, S.; Zhu, H.; Ding, B.; Cai, Y.; Ni, J.; Wu, Q.; Meng, Q.; Zhang, X.; Zhang, C.; Li, X.; Wang, M.; Chen, R.; Jin, H.; Zhang, Z. PSCA rs2294008 polymorphism contributes to the decreased risk for cervical cancer in a Chinese population. Sci. Rep., 2016, 6, 23465.
[http://dx.doi.org/10.1038/srep23465] [PMID: 27001215]
[172]
Zidi, S.; Stayoussef, M.; Alsaleh, B.L.; Gazouani, E.; Mezlini, A.; Ebrahim, B.H.; Yacoubi-Loueslati, B.; Almawi, W.Y. Relationships between Common and Novel Interleukin-6 Gene Polymorphisms and Risk of Cervical Cancer: a Case-Control Study. Pathol. Oncol. Res., 2017, 23(2), 385-392.
[http://dx.doi.org/10.1007/s12253-016-0127-9] [PMID: 27722983]
[173]
Lutkowska, A.; Roszak, A.; Lianeri, M.; Sowińska, A.; Sotiri, E.; Jagodziński, P.P. Analysis of rs8067378 Polymorphism in the Risk of Uterine Cervical Cancer from a Polish Population and its Impact on Gasdermin B Expression. Mol. Diagn. Ther., 2017, 21(2), 199-207.
[http://dx.doi.org/10.1007/s40291-017-0256-1] [PMID: 28120299]
[174]
Gong, J.M.; Shen, Y.; Shan, W.W.; He, Y.X. The association between MTHFR polymorphism and cervical cancer. Sci. Rep., 2018, 8(1), 7244.
[http://dx.doi.org/10.1038/s41598-018-25726-9] [PMID: 29740106]
[175]
Li, L.; Liu, J.; Liu, C.; Lu, X. The correlation between TNF-α-308 gene polymorphism and susceptibility to cervical cancer. Oncol. Lett., 2018, 15(5), 7163-7167.
[http://dx.doi.org/10.3892/ol.2018.8246] [PMID: 29725439]
[176]
Campitelli, M.; Jeannot, E.; Peter, M.; Lappartient, E.; Saada, S.; de la Rochefordière, A.; Fourchotte, V.; Alran, S.; Petrow, P.; Cottu, P.; Pierga, J.Y.; Lantz, O.; Couturier, J.; Sastre-Garau, X. Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PLoS One, 2012, 7(8)e43393
[http://dx.doi.org/10.1371/journal.pone.0043393] [PMID: 22937045]
[177]
Takakura, M.; Matsumoto, T.; Nakamura, M.; Mizumoto, Y.; Myojyo, S.; Yamazaki, R.; Iwadare, J.; Bono, Y.; Orisaka, S.; Obata, T.; Iizuka, T.; Kagami, K.; Nakayama, K.; Hayakawa, H.; Sakurai, F.; Mizuguchi, H.; Urata, Y.; Fujiwara, T.; Kyo, S.; Sasagawa, T.; Fujiwara, H. Detection of circulating tumor cells in cervical cancer using a conditionally replicative adenovirus targeting telomerase-positive cells. Cancer Sci., 2018, 109(1), 231-240.
[http://dx.doi.org/10.1111/cas.13449] [PMID: 29151279]
[178]
Wen, Y.F.; Cheng, T.T.; Chen, X.L.; Huang, W.J.; Peng, H.H.; Zhou, T.C.; Lin, X.D.; Zeng, L.S. Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy. PLoS One, 2018, 13(10)e0204334
[http://dx.doi.org/10.1371/journal.pone.0204334] [PMID: 30303986]
[179]
Su, Y.F.; Wu, T.F.; Ko, J.L.; Tsai, H.T.; Tee, Y.T.; Chien, M.H.; Chou, C.H.; Lin, W.L.; Low, H.Y.; Chou, M.Y.; Yang, S.F.; Wang, P.H. The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. PLoS One, 2014, 9(3)e91644
[http://dx.doi.org/10.1371/journal.pone.0091644] [PMID: 24637958]
[180]
Zhou, X; Xu, CJ; Wang, JX; Dai, T; Ye, YP; Cui, YM; Liao, WT; Wu, XL; Ou, JP Metastasis-Associated in Colon Cancer-1 Associates With Poor Prognosis and Promotes Cell Invasion and Angiogenesis in Human Cervical Cancer., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, 25(8), 1353-1363.
[http://dx.doi.org/10.1097/IGC.0000000000000524]
[181]
Wang, H.R.; Li, Y.C.; Guo, H.Q.; Yu, L.L.; Wu, Z.; Yin, J.; Liao, G.D.; Qu, Y.M.; Jiang, Y.; Wang, D.; Chen, W. A cocktail of p16INK4a and Ki-67, p16INK4a and minichromosome maintenance protein 2 as triage tests for human papillomavirus primary cervical cancer screening. Oncotarget, 2017, 8(48), 83890-83899.
[http://dx.doi.org/10.18632/oncotarget.19870] [PMID: 29137390]
[182]
Shi, W.J.; Liu, H.; Wu, D.; Tang, Z.H.; Shen, Y.C.; Guo, L. E6/E7 proteins are potential markers for the screening and diagnosis of cervical pre-cancerous lesions and cervical cancer in a Chinese population. Oncol. Lett., 2017, 14(5), 6251-6258.
[http://dx.doi.org/10.3892/ol.2017.6932] [PMID: 29113275]
[183]
Zhu, L.; Zheng, X.; Du, Y.; Xing, Y.; Xu, K.; Cui, L. Matrix metalloproteinase-7 may serve as a novel biomarker for cervical cancer. OncoTargets Ther., 2018, 11, 4207-4220.
[http://dx.doi.org/10.2147/OTT.S160998] [PMID: 30050312]
[184]
Barrón, E.V.; Roman-Bassaure, E.; Sánchez-Sandoval, A.L.; Espinosa, A.M.; Guardado-Estrada, M.; Medina, I.; Juárez, E.; Alfaro, A.; Bermúdez, M.; Zamora, R.; García-Ruiz, C.; Gomora, J.C.; Kofman, S.; Pérez-Armendariz, E.M.; Berumen, J. CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer. PLoS One, 2015, 10(9)e0137397
[http://dx.doi.org/10.1371/journal.pone.0137397] [PMID: 26372210]
[185]
Dürst, M.; Hoyer, H.; Altgassen, C.; Greinke, C.; Häfner, N.; Fishta, A.; Gajda, M.; Mahnert, U.; Hillemanns, P.; Dimpfl, T.; Lenhard, M.; Petry, K.U.; Runnebaum, I.B.; Schneider, A. Prognostic value of HPV-mRNA in sentinel lymph nodes of cervical cancer patients with pN0-status. Oncotarget, 2015, 6(26), 23015-23025.
[http://dx.doi.org/10.18632/oncotarget.4132] [PMID: 26008982]
[186]
Sørbye, S.W.; Fismen, S.; Gutteberg, T.J.; Mortensen, E.S.; Skjeldestad, F.E. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study. BMJ Open, 2016, 6(8)e011981
[http://dx.doi.org/10.1136/bmjopen-2016-011981] [PMID: 27515759]
[187]
Ma, Q.; Wan, G.; Wang, S.; Yang, W.; Zhang, J.; Yao, X. Serum microRNA-205 as a novel biomarker for cervical cancer patients. Cancer Cell Int., 2014, 14, 81.
[http://dx.doi.org/10.1186/s12935-014-0081-0] [PMID: 25788864]
[188]
Luo, M.; Shen, D.; Wang, W.; Xian, J. Aberrant expression of microRNA-26b and its prognostic potential in human cervical cancer. Int. J. Clin. Exp. Pathol., 2015, 8(5), 5542-5548.
[PMID: 26191262]
[189]
Liu, P.; Xin, F.; Ma, C.F. Clinical significance of serum miR-196a in cervical intraepithelial neoplasia and cervical cancer. Genet. Mol. Res., 2015, 14(4), 17995-18002.
[http://dx.doi.org/10.4238/2015.December.22.25] [PMID: 26782446]
[190]
Sun, L.; Jiang, R.; Li, J.; Wang, B.; Ma, C.; Lv, Y.; Mu, N. MicoRNA-425-5p is a potential prognostic biomarker for cervical cancer. Ann. Clin. Biochem., 2017, 54(1), 127-133.
[http://dx.doi.org/10.1177/0004563216649377] [PMID: 27166306]
[191]
Park, S.; Eom, K.; Kim, J.; Bang, H.; Wang, H.Y.; Ahn, S.; Kim, G.; Jang, H.; Kim, S.; Lee, D.; Park, K.H.; Lee, H. MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer. BMC Cancer, 2017, 17(1), 658.
[http://dx.doi.org/10.1186/s12885-017-3642-5] [PMID: 28934937]
[192]
Li, M.; Li, B.Y.; Xia, H.; Jiang, L.L. Expression of microRNA-142-3p in cervical cancer and its correlation with prognosis. Eur. Rev. Med. Pharmacol. Sci., 2017, 21(10), 2346-2350.
[PMID: 28617557]
[193]
Nagamitsu, Y.; Nishi, H.; Sasaki, T.; Takaesu, Y.; Terauchi, F.; Isaka, K. Profiling analysis of circulating microRNA expression in cervical cancer. Mol. Clin. Oncol., 2016, 5(1), 189-194.
[http://dx.doi.org/10.3892/mco.2016.875] [PMID: 27330796]
[194]
Xin, F.; Liu, P.; Ma, C.F. A circulating serum miRNA panel as early detection biomarkers of cervical intraepithelial neoplasia. Eur. Rev. Med. Pharmacol. Sci., 2016, 20(23), 4846-4851.
[PMID: 27981553]
[195]
Carow, K.; Gölitz, M.; Wolf, M.; Häfner, N.; Jansen, L.; Hoyer, H.; Schwarz, E.; Runnebaum, I.B.; Dürst, M. Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA. Int. J. Mol. Sci., 2017, 18(10)E2032
[http://dx.doi.org/10.3390/ijms18102032] [PMID: 28937589]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy